Cited by 138Cannabis and Cannabinoid ResearchMedicinal Plant Extracts EffectsAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety

FABRE, LOUIS F., McLENDON, DAVID·1981·The Journal of Clinical Pharmacology

DOI 10.1002/j.1552-4604.1981.tb02617.x

Open this paper in CoChat — free account

Abstract

Abstract: The anxiolytic properties of nabilone, a synthetic cannabinoid resembling the natural cannabinoids, were studied in 25 outpatients suffering from anxiety. The drug was compared with a placebo in a double‐blind manner over a 28‐day treatment period. Patients were seen weekly by the physician and were rated by the Hamilton Rating Scale for Anxiety and the Patient's Global Evaluation as well as by patient‐rated evaluations. The results of the study showed a dramatic improvement in anxiety in the nabilone group when compared with placebo ( P < 0.001). Side effects reported were dry mouth, dry eyes, and drowsiness. Patients did not report any of the subjective “altered state” experience of marihuana.

Integrity signals

Registry

Crossref · 10.1002/j.1552-4604.1981.tb02617.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 350
Clinical pharmacology of nabilone, a cannabinol derivative
Lemberger, L., & Rowe, H. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975186720 · Cited by 74
A model for evaluation of antianxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam
Nakano, S., Gillespie, H. K., & Hollister, L. E. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197823154 · Cited by 59
Single‐Dose Study of Nabilone in Anxious Volunteers
Glass, R. M., UHLENHUTH, E. H., Hartel, F. W., Schuster, C. R., & Fischman, M. W. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02618.x · Cited by 45
Does marijuana enhance experimentally induced anxiety?
Pillard, R. C., McNair, D. M., & Fisher, S. (1974) · Psychopharmacology · doi:10.1007/bf00429414 · Cited by 30
Changes in Anxiety Feelings Following Marihuana Smoking
Abel, E. L. (1971) · British Journal of Addiction to Alcohol & Other Drugs · doi:10.1111/j.1360-0443.1971.tb02384.x · Cited by 25
Suppression of the cardiac conditioned response by ?-9-tetrahydrocannabinol: A comparison with other drugs
McLendon, D. M., Harris, R. T., & Maule, W. F. (1976) · Psychopharmacology · doi:10.1007/bf00430486 · Cited by 13
Self-citation

Show all 7 references

Research works printed but not linked: 4

Braude MC, 1975, International Conference on the Pharmacology of Cannabis.
Stark P, 1975, Preclinical pharmacologic profile of psychoactive cannabinoid, Pharmacologist., 17, 210
Fabre L, 1978, Nabilone, a cannabinoid, in the treatment of anxiety: an open‐label and double‐blind study, Curr Therap Res., 24, 161
Ilaria R, 1978, Nabilone: a cannabinol derivative in anxiety neurosis, Fed Proc., 37, 6

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Interneuron Diversity series: Rhythm and mood in perisomatic inhibition
Freund, T. F. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00227-3 · Cited by 641
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354
The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)
Fraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283
Therapeutic aspects of cannabis and cannabinoids
Robson, P. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.2.107 · Cited by 265
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder
Hill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 250
Amygdala FAAH and anandamide: mediating protection and recovery from stress
Gunduz-Cinar, O., Hill, M. N., McEwen, B. S., & Holmes, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.008 · Cited by 229
The endocannabinoid nervous system
Porter, A. C., & Felder, C. C. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00130-9 · Cited by 226
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 227
Adverse effects of cannabis and cannabinoids
Ashton, C. H. (1999) · British Journal of Anaesthesia · doi:10.1093/bja/83.4.637 · Cited by 214
Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?
Hill, M. N., & Gorzalka, B. B. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00006 · Cited by 196
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy
Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019) · Scientific Reports · doi:10.1038/s41598-018-37570-y · Cited by 186
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184
Adult Neurogenesis and Mental Illness
Schoenfeld, T. J., & Cameron, H. A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.230 · Cited by 192
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Trends in the Development of New Antidepressants. Is there a Light at the End of the Tunnel?
Pacher, P., & Kecskeméti, V. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455594 · Cited by 182
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
Lim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 150
Endocannabinoid system dysfunction in mood and related disorders
Ashton, C. H., & Moore, P. B. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01687.x · Cited by 150
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 146
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential
Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051541 · Cited by 135
Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses
Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 120
Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial
Pini, L. A., Guerzoni, S., Cainazzo, M. M., Ferrari, A., Sarchielli, P., Tiraferri, I., Ciccarese, M., & Zappaterra, M. (2012) · The Journal of Headache and Pain · doi:10.1007/s10194-012-0490-1 · Cited by 107
Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Turna, J., Patterson, B. A., & Ameringen, M. V. (2017) · Depression and Anxiety · doi:10.1002/da.22664 · Cited by 107
Experience with the Synthetic Cannabinoid Nabilone in Chronic Noncancer Pain
Berlach, D. M., Shir, Y., & Ware, M. A. (2006) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00085.x · Cited by 96
A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting
Ware, M. A. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1132 · Cited by 89
Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives
Tambaro, S., & Bortolato, M. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842269 · Cited by 93
Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review
Stanciu, C. N., Brunette, M. F., Teja, N., & Budney, A. J. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000189 · Cited by 94
Endocannabinoids, cannabinoids and the regulation of anxiety
Petrie, G. N., Nastase, A. S., Aukema, R. J., & Hill, M. N. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108626 · Cited by 91
Uso terapêutico dos canabinoides em psiquiatria
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 93
Human Studies of Cannabinoids and Medicinal Cannabis
Robson, P. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_25 · Cited by 78
Spray freeze drying to produce a stable Δ9-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation
van Drooge, D. J., Hinrichs, W. L. J., Dickhoff, B. H. J., Elli, M., Visser, M. R., Zijlstra, G. S., & Frijlink, H. W. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.06.007 · Cited by 73
Classical and novel approaches to the preclinical testing of anxiolytics: A critical evaluation
Haller, J., Aliczki, M., & Gyimesi-Pelczer, K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.09.001 · Cited by 70
Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users
Turna, J., Simpson, W. S., Patterson, B. A., Lucas, P., & Ameringen, M. V. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.024 · Cited by 69
Safety Considerations in Cannabinoid-Based Medicine
Gottschling, S., Ayonrinde, O., Bhaskar, A., Blockman, M., D’Agnone, O., Schecter, D., Rodríguez, L. D. S., Yafai, S., & Cyr, C. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s275049 · Cited by 72
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Hasbi, A., Madras, B. K., & George, S. R. (2023) · Brain Sciences · doi:10.3390/brainsci13020325 · Cited by 69
Developmental regulation of fear learning and anxiety behavior by endocannabinoids
Lee, T. T.-Y., Hill, M. N., & Lee, F. S. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12253 · Cited by 71
The abuse potential of the synthetic cannabinoid nabilone
Ware, M. A., & St Arnaud‐Trempe, E. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02776.x · Cited by 66
Meet Your Stress Management Professionals: The Endocannabinoids
deRoon‐Cassini, T. A., Stollenwerk, T. M., Beatka, M. J., & Hillard, C. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.002 · Cited by 67
Targeting the endocannabinoid system to treat anxiety-related disorders
Korem, N., Zer‐Aviv, T. M., Ganon-Elazar, E., Abush, H., & Akirav, I. (2015) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2015-0058 · Cited by 69
Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial
Martin, E. L., Strickland, J. C., Schlienz, N. J., Munson, J., Jackson, H., Bonn‐Miller, M. O., & Vandrey, R. G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.729800 · Cited by 62
Nabilone
Ward, A., & Holmes, B. (1985) · Drugs · doi:10.2165/00003495-198530020-00002 · Cited by 59
Cannabinoid receptor genes
Onaivi, E. S., Chakrabarti, A. K., & Chaudhuri, G. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00044-5 · Cited by 55
The Endocannabinoid System and Anxiety
Lisboa, S. F. D. S., Gomes, F. V., Terzian, A. L. B., de Aguiar, D. C., Moreira, F. A., Resstel, L. B. M., & Guimarães, F. S. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.09.006 · Cited by 56
Cannabis and the Anxiety of Fragmentation—A Systems Approach for Finding an Anxiolytic Cannabis Chemotype
Kamal, B., Kamal, F., & Lantela, D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00730 · Cited by 59
Cannabis use improves retention and virological outcomes in patients treated for hepatitis C
Sylvestre, D. L., Clements, B. J., & Malibu, Y. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/01.meg.0000216934.22114.51 · Cited by 54
Solid dispersions based on inulin for the stabilisation and formulation of Δ9-tetrahydrocannabinol
van Drooge, D. J., Hinrichs, W. L. J., Wegman, K. A. M., Visser, M. R., Eissens, A. C., & Frijlink, H. W. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.11.014 · Cited by 49
Cannabinoid Modulation of Fear Extinction Brain Circuits: A Novel Target to Advance Anxiety Treatment
Rabinak, C. A., & Phan, K. L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990437 · Cited by 49
Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W. M., Meyer, J. H., Crockford, D. N., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.044 · Cited by 44
The role of cannabis in treating anxiety
Ameringen, M. V., Zhang, J., Patterson, B. A., & Turna, J. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000566 · Cited by 43
Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence
Célèrier, E., Ahdepil, T., Wikander, H., Berrendero, F., Nyberg, F., & Maldonado, R. J. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.017 · Cited by 43
Cannabinoids as therapeutic for PTSD
Loflin, M., Babson, K. A., & Bonn‐Miller, M. O. (2016) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2016.12.001 · Cited by 44
Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies
Raymundi, A. M., da Silva, T. R., Sohn, J. M. B., Bertoglio, L. J., & Stern, C. A. J. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02813-8 · Cited by 43
Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs
Batista, L. A., Gobira, P. H., Viana, T. G., de Aguiar, D. C., & Moreira, F. A. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000073 · Cited by 38
UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder
Ergisi, M., Erridge, S., Harris, M., Kawka, M., Nimalan, D., Salazar, O., Loupasaki, K., Ali, R., Holvey, C., Coomber, R., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2020640 · Cited by 40
Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis
Bahji, A., Meyyappan, A. C., & Hawken, E. R. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.07.030 · Cited by 39
Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence
Chye, Y., Kirkham, R., Lorenzetti, V., McTavish, E., Solowij, N., & Yücel, M. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.009 · Cited by 34
Influence of plasticizers on the stability and release of a prodrug of Δ9-tetrahydrocannabinol incorporated in poly (ethylene oxide) matrices
Thumma, S., ElSohly, M. A., Zhang, S., Gul, W., & Repka, M. A. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.06.009 · Cited by 34
Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review
Bouquié, R., Deslandes, G., Mazaré, H., Cogné, M., Mahé, J., Grégoire, M., & Jolliet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12373 · Cited by 34
Drugs related to tetrahydrocannabinol
Razdan, R. K., & Howes, J. F. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030203 · Cited by 32
Cannabis as medicine: time for the phoenix to rise?
Robson, P. (1998) · BMJ · doi:10.1136/bmj.316.7137.1034 · Cited by 32
Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus
Costiniuk, C. T., Mills, E. J., & Cooper, C. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/725702 · Cited by 30
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 29
Biomedical benefits of cannabinoids?
Ashton, C. H. (1999) · Addiction Biology · doi:10.1080/13556219971623 · Cited by 22
Navigating Blind in the Green Rush: Clinical Considerations and Harm Reduction Practices for Cannabis
Meffert, B. N., Morabito, D. M., Mosich, M. K., Loflin, M., Sottile, J. E., & Heinz, A. J. (2018) · Current Drug Research Reviews · doi:10.2174/2589977511666181109153958 · Cited by 22
Cannabinoids in anaesthesia and pain therapy
Azad, S. C., & Rammes, G. (2005) · Current Opinion in Anaesthesiology · doi:10.1097/01.aco.0000174959.05383.9c · Cited by 19
Khat (Catha edulis F.) and cannabinoids: Parallel and contrasting behavioral effects in preclinical and clinical studies
Kibret, B. G. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.09.019 · Cited by 18
Cannabis
(1998) · CRC Press eBooks · doi:10.1201/9780203304228 · Cited by 16
Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis
Belgers, V., Röttgering, J. G., Douw, L., Klein, M., Ket, J. C. F., van de Ven, P. M., Würdinger, T., Linde, M. E. V., Niers, J. M., Weber, M., et al. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0187 · Cited by 19
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis
Bortolato, M., Bini, V., & Tambaro, S. (2010) · Pharmaceuticals · doi:10.3390/ph3092799 · Cited by 17
The differential effects of medicinal cannabis on mental health: A systematic review
de Bode, N., Kroon, E., Sznitman, S. R., & Cousijn, J. (2025) · Clinical Psychology Review · doi:10.1016/j.cpr.2025.102581 · Cited by 13
Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?
Tibbo, P. G., McKee, K. A., Meyer, J. H., Crocker, C. E., Aitchison, K. J., Lam, R. W. M., & Crockford, D. N. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720945525 · Cited by 13
Uso terapéutico de los cannabinoides
Durán, M., & Capellà, D. (2004) · Adicciones · doi:10.20882/adicciones.412 · Cited by 13
Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial
Tavhare, S. D., Acharya, R., Reddy, R. G., & Dhiman, K. S. (2019) · AYU (An International Quarterly Journal of Research in Ayurveda) · doi:10.4103/ayu.ayu_43_19 · Cited by 12
Tetrahydrocannabinols: potential cannabimimetic agents for cancer therapy
Prateeksha, P., Sharma, V. K., Singh, S. M., Sharma, M., Diwan, D., Hesham, A. E., Guleria, S., Nguyen, Q. D., Gupta, V. K., & Singh, B. N. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10078-2 · Cited by 11
Comparison of Bronchial Effects of Nabilone and Terbutaline in Healthy and Asthmatic Subjects
Gong, H., Tashkin, D. P., & Calvarese, B. M. (1983) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1983.tb02715.x · Cited by 11
Adverse Ocular Impact and Emerging Therapeutic Potential of Cannabis and Cannabinoids: A Narrative Review
Bondok, M., Nguyen, A. X.-L., Landó, L., & Wu, A. Y. (2024) · Clinical ophthalmology · doi:10.2147/opth.s501494 · Cited by 11
Higher odds of irritable bowel syndrome among hospitalized patients using cannabis: a propensity-matched analysis
Adejumo, A., Ajayi, T. O., Adegbala, O. M., & Bukong, T. N. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001382 · Cited by 10
The Synthetic Analog of Δ9-Tetrahydrocannabinol (THC): Nabilone. Pharmacology and Clinical Application
Balter, R. E., & Haney, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00099-5 · Cited by 10
Medicinal cannabis in the management of anxiety disorders: A systematic review
Roberts, L., Sorial, E., Budgeon, C. A., Lee, K., Preen, D. B., & Cumming, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116552 · Cited by 11
Synthetic Cannabinoids
(2014) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63430-6.00009-6 · Cited by 8
Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys
Delatte, M. S., & Paronis, C. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0918-5 · Cited by 8
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7
Utilidad terapéutica del Cannabis y derivados
Lorenzo, P., & Leza, J. C. (2000) · Adicciones · doi:10.20882/adicciones.678 · Cited by 7
Cannabinoid-Based Drugs: Potential Applications in Addiction and Other Mental Disorders
Don, W., & Piomelli, D. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150009 · Cited by 7
Cannabis
Robson, P. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.2.164 · Cited by 6
Cannabis Science and Therapeutics: An Overview for Clinicians
Sera, L., & Hempel-Sanderoff, C. (2023) · Journal of clinical pharmacology · doi:10.1002/jcph.2400 · Cited by 2
Naturalistic examination of the anxiolytic effects of medical cannabis and associated gender and age differences in a Canadian cohort
Minhas, M., & Lunn, S. E. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00192-x · Cited by 4
An EEG investigation on nabilone, a synthetic cannabinoid, in rabbits
Sagratella, S., Pèzzola, A., & de Carolis, A. S. (1986) · Pharmacological Research Communications · doi:10.1016/0031-6989(86)90107-4 · Cited by 4
Measurement of Korean EFL college students' foreign language classroom speaking anxiety: evidence of psychometric properties and accuracy of a computerized adaptive test (CAT) with dichotomously scored items using a CAT simulation
Yang, T.-K. (2005) · Texas ScholarWorks (Texas Digital Library) · Cited by 4
Unseen dualities: underdiagnosis of substance use disorders in borderline personality disorder
Nabel, J., Bertele, S., Stapel, B., Scharn, N., & Kahl, K. G. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1539611 · Cited by 3
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_465-1 · Cited by 3
Choosing a Product, Route of Administration, Initial Dosage, Titration, Monitoring and Management of Adverse Effects
Schecter, D., & Cyr, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-89918-9_7 · Cited by 3
Use of cannabis in medicine and pharmacy
Goločorbin-Kon, S., Pavlović, N., Rašković, A., Lalic-Popovic, M. N., Milić, N., Milosevic, N. P., & Mikov, M. (2015) · Medicinski casopis · doi:10.5937/mckg49-9796 · Cited by 3
Interaction Between L-Type Calcium Channels and Antagonist of Cannabinoid System on Anxiety in Male Rat
Komaki‬, A., Haghgooyan, A., Shahidi, ‬., Sarihi, A., & Salehi, I. (2014) · Avicenna Journal of Neuro Psych Physiology · doi:10.17795/ajnpp-24450 · Cited by 2

Authors: FABRE, L. F., & McLENDON, D.
Venue: The Journal of Clinical Pharmacology
Publisher: Wiley
Published: 1981-08-09
Volume: 21
Issue: S1
Pages: 377S-382S
ISSN: 0021-9754 (ISSN-L)
0091-2700
1552-4604
DOI: 10.1002/j.1552-4604.1981.tb02617.x
OpenAlex: W2140255682
Cited by: 138
References: 7
Citations by year: 2026: 1 · 2025: 5 · 2024: 4 · 2023: 13 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 5 · 2013: 3 · 2012: 4
FWCI: 0.82
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 11534 d)
Locations: The Journal of Clinical Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: nabilone, synthetic cannabinoids, anxiety, anxiolytic efficacy, drug safety, placebo comparison, adverse effects, xerostomia, sleepiness, cannabis
MeSH terms: Adolescent, Adult, Anxiety Disorders, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Dronabinol, Time Factors, Anti-Anxiety Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks